Your browser doesn't support javascript.
loading
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard, I; Leary, A; Pignata, S; Cropet, C; González-Martín, A; Marth, C; Nagao, S; Vergote, I; Colombo, N; Mäenpää, J; Selle, F; Sehouli, J; Lorusso, D; Guerra Alia, E M; Bogner, G; Yoshida, H; Lefeuvre-Plesse, C; Buderath, P; Mosconi, A M; Lortholary, A; Burges, A; Medioni, J; El-Balat, A; Rodrigues, M; Park-Simon, T-W; Dubot, C; Denschlag, D; You, B; Pujade-Lauraine, E; Harter, P.
Affiliation
  • Ray-Coquard I; Department of Medical Oncology, Centre Léon Bernard, Lyon, France; GINECO, France. Electronic address: isabelle.ray-coquard@lyon.unicancer.fr.
  • Leary A; GINECO, France; Gynecological Cancer Unit, Department of Medicine, Institut Gustave Roussy, Villejuif France.
  • Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Naples, Italy; MITO, Italy.
  • Cropet C; GINECO, France; Department of Biostatistics Centre Léon BERARD, Lyon, France.
  • González-Martín A; Department of Medical Oncology, Clínica Universidad de Navarra, Program in Solid Tumors (CIMA), Pamplona, Spain; GEICO, Spain.
  • Marth C; Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria; AGO Austria, Austria.
  • Nagao S; Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi, Japan; GOTIC, Japan.
  • Vergote I; Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; BGOG, Belgium, European Union.
  • Colombo N; University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS, Milan, Italy; MANGO, Italy.
  • Mäenpää J; Department of Obstetrics and Gynecology and Cancer Center, Tampere University and University Hospital, Tampere, Finland; NSGO, Nordics.
  • Selle F; GINECO, France; Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.
  • Sehouli J; Charité - Department of Gynecology with Center of Oncological Surgery, Universitätsmedizin Berlin, Berlin, Germany; AGO, Germany.
  • Lorusso D; MITO, Italy; Gynecologic Oncology Unit, Catholic University of Sacred Heart and Fondazione Policlinico Gemelli IRCCS, Rome Italy.
  • Guerra Alia EM; GEICO, Spain; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Bogner G; AGO Austria, Austria; Department of Obstetrics and Gynecology, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Yoshida H; GOTIC, Japan; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Lefeuvre-Plesse C; GINECO, France; Department of Medical Oncology, Centre Eugène Marquis, Rennes France.
  • Buderath P; AGO, Germany; Universitätsklinikum Essen, University Hospital Essen, West German Cancer Center, Department of Gynecology and Obstetrics, Essen, Germany.
  • Mosconi AM; MITO, Italy; S.C. di Oncologia Medica Osp. S. Maria della Misericordia - AO di Perugia, Perugia, Italy.
  • Lortholary A; GINECO, France; Centre Catherine de Sienne Hopital Privé du Confluent, Nantes, France.
  • Burges A; AGO, Germany; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
  • Medioni J; GINECO, France; Hôpital Européen Georges Pompidou, Universite de Paris Cite, Paris, France.
  • El-Balat A; AGO, Germany; Spital Uster, Frauenklinik, Uster, Switzerland; Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany.
  • Rodrigues M; GINECO, France; Department of Medical Oncology, Institut Curie, Hopital Claudius Régaud, PSL Research University, Paris, France.
  • Park-Simon TW; AGO, Germany; Department of Gynaecology and Obstetrics, Hannover Medical School, Hanover, Germany.
  • Dubot C; GINECO, France; Oncologie Médicale, Institut Curie, Hôpital René Huguenin, Saint Cloud, Paris, France.
  • Denschlag D; AGO, Germany; Hochtaunuskliniken, Bad Homburg, Germany.
  • You B; GINECO, France; HCL - Hospices Civils de Lyon IC-HCL, CITOHL, Université Claude Bernard Lyon 1, CICLY, Lyon, France.
  • Pujade-Lauraine E; Medical Oncology Department, ARCAGY Research, Paris, France.
  • Harter P; AGO, Germany; Department of Gynaecology & Gynaecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.
Ann Oncol ; 34(8): 681-692, 2023 08.
Article in En | MEDLINE | ID: mdl-37211045
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Guideline Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Guideline Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article